IL23A: A Protein Involved in Immune Response and Disease (G51561)

Target Name: IL23A

NCBI ID: G51561

IL23A

IL23A: A Protein Involved in Immune Response and Disease

IL23A, also known as Interleukin 23 alpha subunit p19, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the interleukin family, which is a group of cytokines that play a crucial role in the immune system. IL23A is one of the proteins that is produced by the immune cells when they are activated.

IL23A is a cytokine that is involved in the regulation of inflammation and immune responses. It is a potent chemoattractant, which means that it can attract other cells to its surface. This is important for the immune system because it allows them to track and destroy infected or damaged cells. IL23A is also involved in the regulation of cell growth and differentiation.

The IL23A protein is produced by the immune cells when they are activated. When an immune cell is activated, it produces a large amount of IL23A. This protein is then released into the surrounding tissue, where it can interact with other immune cells and stimulate them to take action.

IL23A has been shown to play a role in a variety of diseases and conditions, including cancer, autoimmune diseases, and obesity. For example, studies have shown that high levels of IL23A are associated with an increased risk of cancer, including breast and colon cancer. IL23A has also been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

In addition to its potential role in disease, IL23A is also a drug target. Researchers are studying the potential uses of IL23A as a treatment for a variety of conditions, including cancer, autoimmune diseases, and obesity. One of the main goals of these studies is to develop drugs that can inhibit the activity of IL23A and reduce its production.

IL23A is also an attractive biomarker for cancer diagnosis and monitoring. The level of IL23A produced by cancer cells can be easily measured, which makes it a useful marker for tracking the effectiveness of cancer treatments. Researchers are also studying the relationship between IL23A and cancer risk, with a focus on identifying biomarkers that can be used to predict the risk of cancer and guide cancer treatment decisions.

Overall, IL23A is a protein that is involved in the regulation of inflammation and immune responses. It is a potent chemoattractant that can attract other cells to its surface, and it is also involved in the regulation of cell growth and differentiation. The level of IL23A produced by immune cells when they are activated is a potential drug target and a useful biomarker for cancer diagnosis and monitoring. Further research is needed to fully understand the role of IL23A in these processes and to develop effective treatments for the prevention and treatment of disease.

Protein Name: Interleukin 23 Subunit Alpha

Functions: Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity (PubMed:11114383). Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4 (PubMed:32474165, PubMed:29287995, PubMed:33606986). This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A (PubMed:12023369). In turn, participates in the early and effective intracellular bacterial clearance (PubMed:32474165). Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells (PubMed:17676044)

The "IL23A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL23A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets